Health & Education · Madrid

Antibiotic-resistant infections surge in Europe, with Klebsiella up 72% since 2019

Bloodstream infections from carbapenem-resistant Klebsiella pneumoniae rose 72% in Europe between 2019 and 2025, the European Centre for Disease Prevention and Control said on Wednesday, 18 November.

AI text based on reports by El Confidencial, La Razón, Mediafax.ro and other publishers. Published . How it is made

For membersThe first 30 seconds for everyone. Synthetic voice (AI).

In brief

Madrid · Spain

Klebsiella leads the rise

The European Centre for Disease Prevention and Control (ECDC) published its latest antimicrobial resistance reports on Wednesday, 18 November, to mark European Antibiotic Day. Bloodstream infections caused by carbapenem-resistant Klebsiella pneumoniae grew 72% between 2019 and 2025, far off the EU target of a 5% cut by 2030. Infections from E. coli resistant to third-generation cephalosporins rose 16.4% over the same period, against a 2030 goal of a 10% reduction. The agency says several Klebsiella strains now resist nearly all antibiotics, including the newest ones, and that the infection carries a mortality rate typically between 40% and 70%.

Change in resistant infections, 2019 to 2025, EU%
Klebsiella pneumoniae (carbapenem-resistant bloodstream)
72 %
E. coli (third-generation cephalosporin-resistant)
16.4 %
MRSA (bloodstream)
-19 %

Data from the article text

Hospitals and prevention

Christian Giske, who coordinates the ECDC's work on this topic, called the Klebsiella findings 'the biggest concern' among all superbug data gathered over the past year. Because the bacterium passes between patients, the agency calls for stricter infection prevention in hospitals, including rigorous hand hygiene, correct use of gloves and protective equipment, and thorough cleaning and disinfection of surfaces. Giske argued that measures which worked against MRSA may not be enough for Klebsiella, which can form stronger reservoirs in the body. MRSA bloodstream infections fell 19% in 2025 compared with 2019, and the report says the EU is on track on that target, although rises in the last two years threaten the progress. ECDC director Pamela Rendi-Wagner said the EU still lags on several of its 2030 targets for fighting antimicrobial resistance.

Antibiotic use barely falling

Antibiotic consumption in 2025 was only 5% below 2019 levels, against a target of a 20% cut by 2030. The share of first-line antibiotics on the World Health Organization list rose from 61.1% to 62.5%, nearing the 65% goal. The ECDC notes that 90% of human antibiotic use happens in the community or in outpatient settings, which is why this year's campaign targets children, who are often exposed to antibiotics. The campaign's slogan, 'Look after your children: use antibiotics wisely', reminds parents and carers that colds, coughs and sore throats are usually viral and need no antibiotics.

Spain's figures stand out

In Spain, E. coli infections have risen 76.1% since 2019 and Klebsiella pneumoniae infections 67.1%, according to ECDC data for the country. Across the EU, E. coli infections rose 16.4% over the same period, while Spanish MRSA infections rose 5.5% as the EU-wide figure fell 19%. Spain cut antibiotic use by 8.2% since 2019, but its consumption still sits above the EU average, and its first-line share fell 1.4%.

Change since 2019 in Spain, selected resistant infections%
E. coli
76.1 %
Klebsiella pneumoniae
67.1 %
MRSA
5.5 %

Data from the article text

Bruno Gonzalez-Zorn, president of the Antimicrobial Resistance Unit at the Complutense University of Madrid, said decades of antibiotic use have favoured resistant bacteria, and that very few new antibiotic families have arrived in recent decades. The expert points out that many large drugmakers have cut their antibiotic investment, because developing these drugs is expensive and poorly profitable.

Burden and next steps

The ECDC estimates that more than 35,000 people die each year in the EU from antimicrobial-resistant infections, a toll El Pais compares with the combined mortality of influenza, tuberculosis and HIV/AIDS. The WHO warned on Monday of millions of deaths if existing medicines stop working, according to RP Online. Europe's new pharmaceutical legislation is set to be signed into law in December, with a market monopoly perk for industry and steady payment models for countries buying new antibiotics. Rendi-Wagner said faster genome surveillance now helps authorities see how resistant bacteria spread and where new antibiotics are most needed.

Ask about this text

Sources and context

Organizations
European Union

Pollar is free and carries no ads in the text. Its members keep it going.

Support Pollar